Stay updated with breaking news from Angle Plc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline report is expected to rise due to an increased prevalence rate of...
Investegate announcements from Angle PLC, Exercise of options and total voting rights
Angle losses widen in H1 on increased investment spend
26 April 2021 | 09:20am StockMarketWire.com - Liquid biopsy company Angle said it had completed patient enrolment for its ovarian cancer clinical verification study, with headline results expected in the fourth quarter of 2021. The study would support the launch of an ovarian cancer test from Angle's clinical laboratories in the United States and the UK. The study is designed to evaluate the use of Angle's Parsortix system for circulating tumour cell harvest and subsequent downstream analysis with Angle's HyCEAD multiplex RNA platform as a simple blood test to detect the presence of ovarian c...
Headline results are expected in the fourth quarter, investors were told Angle PLC (LON:AGL, OTCQX:ANPCY) said it completed the patient enrolment of 200 women for its ovarian cancer clinical verification study. Scientists and doctors from the University of Rochester Medical Center, New York, will assess the ability of the company’s Parsortix system to detect the presence of ovarian cancer in women with a pelvic mass prior to surgery. The liquid biopsy system will be used to harvest circulating tumour cell (CTC) for analysis with Angle's HyCEAD multiplex RNA platform as a simple blood t...